window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1'); Skip to content
Novigenix Logo Novigenix Logo
  • About us
    • Our Story
    • Team
    • Compliance
    • Commitment to ESG
  • LITOSeek™
    • LITOSeek Platform
    • Translational Medicine
  • News
  • Contact

Omics

By Novigenix|2020-01-20T21:04:27+02:0020 January 2020|

Share this content

FacebookXLinkedInEmail

About the Author: Novigenix

Novigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox®, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. Novigenix’s technology is based on a new generation of predictive gene expression profiles of circulating blood cells and concentration profile of tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures of biomarkers provide new and accurate solutions for the early detection of cancer.

Recents posts

  • Novigenix AI Spin-Out to Accelerate AI-Powered Immune Intelligence 6 March 2026
  • Novigenix AI awarded EUR 1.8M in the groundbreaking BRECISE IHI Consortium to industrialize AI-powered liquid biopsy for prediction of immunotherapy response 31 March 2025
  • New study reveals novel multi-omics approach with unprecedented treatment response prediction in metastatic urothelial cancer 11 March 2025
  • Breakthrough study reveals blood transcriptomic alternations for early detection of colorectal cancer 27 November 2024
  • Understanding Tumor Immunology: How AI-powered blood RNA analysis could unlock immunotherapy prognoses 17 October 2024

Novigenix AI

Novigenix AI is a pioneering TechBio delivering liquid biopsy multi-omic solutions powered by the LITOSeek™ AI-RNA analytics platform to accelerate early cancer detection and development of effective therapies for better patient outcomes.

Contact us

  • Route de la Corniche 3
    Phenyl Building
    CH-1066 Epalinges
    Switzerland
  • partnerships@novigenix.com

Follow us on LinkedIn

Recent posts

  • Novigenix AI Spin-Out to Accelerate AI-Powered Immune Intelligence
  • Novigenix AI awarded EUR 1.8M in the groundbreaking BRECISE IHI Consortium to industrialize AI-powered liquid biopsy for prediction of immunotherapy response

Newsletter

COPYRIGHT 2026 NOVIGENIX AI | ALL RIGHTS RESERVED | PRIVACY POLICY | POWERED BY AGENCE-ACP |
Page load link
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Learn more Ok

Privacy Notice

Go to Top